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Abstract
RNA interference (RNAi) is a highly specific gene-silencing mechanism triggered by small
interfering RNA (siRNA). Effective intracellular delivery requires the development of potent
siRNA carriers. Here, we describe the synthesis and screening of a series of siRNA delivery
materials. Short polyethyleneimine (PEI, Mw 600) was selected as a cationic backbone to which
lipid tails were conjugated at various levels of saturation. In solution these polymer–lipid hybrids
self-assemble to form nanoparticles capable of complexing siRNA. The complexes silence genes
specifically and with low cytotoxicity. The efficiency of gene knockdown increased as the number
of lipid tails conjugated to the PEI backbone increased. This is explained by reducing the binding
affinity between the siRNA strands to the complex, thereby enabling siRNA release after cellular
internalization. These results highlight the importance of complexation strength when designing
siRNA delivery materials.
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1. Introduction
Since its discovery by Fire and Mello [1], RNA interference (RNAi) has been studied pre-
clinically for its potential to silence genes that are associated with cancer [2,3], infection and
inflammation [4], respiratory and neurological disorders [5,6], and autoimmune diseases [7].
Clinical investigations of the therapeutic potential of RNAi are currently under evaluation
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[8,9]. However, additional advances are needed to make broad application of siRNA. This is
explained by a series of hurdles that make delivery difficult. Carriers must bind sufficient
amounts of siRNA, protect it from degradative enzymes, cross the anionic cell membrane
and release the payload into the cytoplasm [3]. Moreover, the carrier must perform these
tasks without damaging the cell. To overcome these hurdles, diverse delivery systems have
been developed. Some of the most effective have been synthesized from cationic polymers,
lipids, and lipid-like materials [10-13].
Amine-based cationic materials have been effective in binding and delivering nucleic acids.
Of these, one of the most rigorously studied is polyethyleneimine (PEI). PEI was first used
as a delivery vehicle for long nucleic strands due to its capacity to form condensed and
stable structures with DNA and RNA [14]. These polyplexes are taken up by cells via
endocytotic pathways [15,16] before being released to the cytosol [16,17]. However, toxicity
and efficacy have both been reported to increase as the molecular weight of PEI increases
[18-20]. More specifically, 25 kDa molecular weight PEI, which has been used in many
studies, is effective, but is toxic to multiple cell lines [19]. Several approaches have been
employed to reduce the toxicity associated with high molecular weight PEI [21,22]. For
example, biodegradable bonds were inserted into the polymer backbone [23-25]. It was
proposed that the long polymer would deliver nucleic payloads effectively and then degrade
into well-tolerated short PEI fragments [26]. Another approach is to conjugate chemical
groups, such as lipids, to high Mw PEI, thereby reducing toxicity [27-30].
Here, we sought to study the ability of low molecular-weight PEI (0.6 kDa) modified with
lipid tails to act as siRNA delivery materials. Our hypothesis was that these short lipid-
polymer hybrids would be well tolerated. Furthermore, we tested the effect of the carriers’
molecular structure on their capacity to induce RNAi. For this, lipid tails were conjugated to
the amine backbone at increasing levels of saturation, and the expression of a targeted gene
was measured. We found that increasing the degree of saturation, up to a point at which the
complex was not stable in solution, was most effective for siRNA delivery.
2. Materials and methods
2.1. Lipid-modified PEI
Polyethyleneimine, ethylendiamine end capped, Mw 600 (Aldrich, Natick, MA) was
conjugated to 1,2-Epoxyoctadecane, MW 268.49 (Alfa Aesar, Ward Hill, MA) via an
epoxide ring-opening reaction as shown schematically in Fig. 1A and described previously
in detail in [11]. In brief, epoxide-terminated C18 alkanes were dissolved in 200-proof
ethanol and reacted with PEI at 90 °C for 48 h. The epoxide: PEI molar ratios were varied
from 0:1 up to 3:1; above this ratio the product formed unstable complexes with siRNA in
water. The product was dissolved in deuterated DMSO and characterized by 1H-NMR (400
MHZ, Bruker, Billerica, MA) (Fig. S2), structures coincide with previous publications on
similar compounds [31-33]. In addition, the product was characterized using Ab42 matrix-
assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry using a
Microflex (Bruker Daltonics, Billerica, MA, USA) equipped with a pulsed nitrogen laser
operating at 337 nm (Fig. S3). Small oligomer positive ion spectra were acquired in reflector
mode over an m/z range from 500 to 6000 using a 20-kV accelerating voltage and a 150-ns
delay extraction time. The spectrum for each spot was obtained by averaging the results of
200 laser shots. In brief, the compounds were dissolved in pure ethanol at 5 mg/mL, 1 μl
was mixed with 100 μl matrix (25 mg dihydroxybenzoic acid (Sigma-Aldrich), 500 μl
methanol, 500 μl H2O); 1 μl was spotted on the grid and let to dry.
Upon hydration, these compounds self-assembled to form nanoparticles in solution. Particles
were sized using dynamic light scattering with a ZetaPALS Zetasizer (Brookhaven
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Instruments, Vienna, Austria). Zeta potential was measured in either 25 mM sodium acetate,
pH 5.3, or 0.1X PBS, pH 7.4, using a 90Plus particle size analyzer (Brookhaven
Instruments).
TEM images were obtained with a JEOL 200CX electron microscope operated at 150 kV.
Samples were prepared on carbon film coated TEM grid and subsequently stained with a 1%
sodium phosphotungstate (PTA) aqueous solution.
2.2. RNAi screening
RNAi was tested using HeLa cells transfected to express both Renilla and firefly luciferase
(a gift from Alnylam Pharmaceuticals, Cambridge, MA) [12].
The compounds were complexed with anti-firefly luciferase siRNA (siLuc) (Dharmacon,
Boulder, Colorado) at an N/P ratio of 14 by incubating with siRNA in 25 mM Na-acetate
(pH 5.2).
Knockdown was measured using the Dual Glo Assay (Promega, Madison, WI), which
quantifies the expression of firefly (target gene) and Renilla (control gene) separately,
thereby calibrating for off-target effects and toxicity [12]. In brief, 15,000 HeLa cells were
plated in a 96-well plate and cultured in 90% DMEM (high glucose, w/ L-glutamine, 25 mM
HEPES, w/o sodium pyruvate; Invitrogen, Carlsbad, CA) 10% FBS (Invitrogen) at 37 °C
under 5% CO2. Twentyfour hours later 20 nM siRNA complexes was added to each well.
The system was incubated overnight and firefly and Renilla gene expression were
quantified.
Knockdown was compared to the levels of luciferase expression in untreated cells.
Lipofectamine-RNAiMax (Invitrogen) at was used as a positive control.
Cellular uptake was examined using Cy5 labeled siRNA (AllStars-Negative Control,
Qiagen, Valencia, CA) with a Perkin Elmer Spinning Disk Confocal Microscope. For this,
50,000 HeLa cells per well were plated in chambered glass coverslips overnight. Cells were
then exposed to labeled nanoparticle/siRNA complexes for 1 h, washed with PBS, and
incubated with Hoescht (2 μg/ml) for nuclear stain.
2.3. siRNA binding affinity
Anti-luciferase siRNA was complexed with the compounds, as described above. Then, Na-
heparin (Sigma) was added at various concentrations, from 0.0002 to 0.075 mg/mL, and
incubated with the complexes for 10 min. The solutions were developed using a 4% agarose
EGel system (Invitrogen) to detect complexation affinity.
2.4. DNA transfection
After aspirating conditioned medium, cells were washed with PBS and detached using 25
μL 0.25% trypsin-EDTA (Invitrogen) per well. 50 μL of FACS running buffer, consisting of
98% PBS, 2% FBS, and 1:200 propidium iodide solution (Invitrogen), was added to each
well. Cells were mixed thoroughly and then transferred to a 96-well round-bottom plate.
GFP expression was measured using FACS on a BD LSR II (Becton Dickinson, San Jose,
CA, USA). Propidium iodide (PI) staining was used to exclude dead cells from the analysis.
2D gating was used to separate increased auto-fluorescence signals from increased GFP
signals to more accurately count positively expressing cells. Gating and analysis were
performed using FlowJo v8.8 software (TreeStar, Ashland, OR, USA).
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This study examines the potential of alkane-modified low molecular weight PEI as siRNA
delivery materials.
Sixteen-carbon-long lipid tails were conjugated to PEI at increasing levels of saturation.
When immersed in aqueous solutions these compounds self-assembled to form
nanoparticles. As the number of tails conjugated to the PEI backbone increased, the size of
the self-assembled particles increased too (Fig. 2A). When having, on average, between one
and two conjugated lipid tails per PEI molecule the compounds self-assembled into ~10-nm
particles in solution. These particles were capable of encapsulating the water-insoluble
hydrophobic drug sorafenib at a 1:5 wt ratio (sor:PEI), thereby suggesting that the particles
have a lipid core [34]. Above two lipid tails conjugated per PEI backbone, the particles
assume a larger size in solution. Conjugating 3 or more lipid tails per PEI molecule resulted
in compounds that aggregated and precipitated in solution. At pH 5.3, from a lipid:PEI mole
ratio of 0.56 the particles had a similar positive zeta potential (~52 mV), enabling efficient
siRNA complexation, while at physiological pH, the zeta increased slightly around
neutrality as the number of lipid tails increased (Fig. 2B).
When complexed with anti-luciferase siRNA the compounds induced RNAi in HeLa cells
expressing both Renilla and firefly luciferase (Fig. 3A). Compounds having less than two
conjugated lipid tails per PEI molecule were significantly less effective in inducing RNAi
(<30% knockdown) in comparison to those having more conjugated lipid tails (~80%
knockdown). Using an unpaired t-test to compare each of the lipids that have more than two
tails to those that have less than two tails, as well as using one-way ANOVA analysis of that
variance, a statistically significant difference of p<0.001 was found. All the compounds
were well tolerated by cells (<20% cell death or off-target silencing). The compounds were
well tolerated by the cells (Fig. 3B).
Our initial hypothesis was that compounds that did not induce significant knockdown were
not entering the cells effectively; however, confocal microscopy conducted using
fluorescently labeled siRNA indicated that all the compounds were capable of delivering
siRNA intracellularly (Fig. 4).
A different mechanism seemed to govern the superiority of some of the complexes in their
ability to induce RNAi. We screened the different compounds for their binding affinity to
siRNA. For this, each of the siRNA–PEI–lipid complexes was treated with Na-heparin (Fig.
5). Heparin encompasses the highest negative charge density of any known natural
compound. When added to dispersions with nucleic polyplexes heparin can replace the
nucleic acid, and thereby be used to titer the affinity between the gene and the complex [35].
Interestingly, as the degree of lipid-tails per PEI increased the affinity of siRNA to the
complex decreased, suggesting that high affinity may inhibit siRNA release from the
complex intracellularly, subsequently inhibiting RNAi (Fig. 6).
Finally, we tested the ability of the most efficacious compounds to deliver green fluorescent
protein (GFP)-encoding DNA plasmid. Transfection efficacy reached only 16.4±4.5%,
suggesting that these compounds are more effective for siRNA delivery, rather than nuclear
delivery of DNA. This was also suggested by the confocal microscopy studies that showed
much of the carrier in cytoplasm (Fig. 4B).
Schroeder et al. Page 4














RNAi has broad clinical applications. Realizing the full potential of RNAi will require
tailoring new delivery materials. Here, we tested the ability of short lipid-modified PEI to
act as siRNA delivery materials.
Sixteen-carbon-long lipid tails were conjugated to a 0.6 kDa PEI backbone at various levels
of saturation. While the compounds were well tolerated, capable of complexing siRNA and
facilitated cellular uptake, we found a structure–function relationship to occur. As the
number of lipid tails attached to the PEI backbone increased, RNAi increased. The increased
number of lipid tails per PEI backbone also translated into lower binding affinity between
siRNA and the complex. Contrarily, compounds that were non-efficacious in inducing RNAi
had high binding affinity to the complex. These data suggest that binding affinity between
siRNA to the delivery material plays a role in facilitating RNAi. High binding affinity may
not enable release of the nucleic cargo after entering the cell, compromising its ability to
take part in the RNAi pathway.
The dependence of the size of the particles on the number of lipid tails conjugated to the PEI
backbone was previously explained by different packing configurations of such polymer–
lipid compounds [36-38]. Having one lipid tail per PEI backbone, the compounds self-
assemble into micelle like structures [36-39] (Fig. 6A). At higher saturation levels the
structure may be liposomal or more complex [36-39] (Fig. 6B).
In conclusion, this study suggests that engineering short amine-based polymer chains
modified with lipid-like materials may prove to be a promising siRNA delivery strategy.
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Conjugating lipid tails to PEI via an epoxide ring opening reaction. (A) A schematic
representation of the chemical reaction. Epoxide terminated alkane was dissolved in ethanol
and reacted with PEI at 90 °C for 48 h to form lipid–PEI hybrids. (B) The molecular weight
of alkane-modified polyethyleneimine as a function of lipid:PEI mole ratio was determined
using matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-
ToF MS).
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The spontaneous self-assembled mean particle size and zeta potential of lipid–PEI
compounds, as a function of the lipid-tail:PEI mole ratio. (A) As the number of conjugated
lipid tails increases — the particle size increases. The polydispersity of the particles was
<0.1. (B) The Zeta potential of the compounds was measured at pH 7.4 and 5.3.
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Gene knockdown capacity of alkylated PEI compounds. RNAi and cell viability were tested
in HeLa cells that express both Renilla and firefly luciferase. (A) Lipid–PEI compounds
were complexed with anti-firefly siRNA and then incubated with the cells. Mean
knockdown levels increased as the number of lipid tails conjugated to the PEI increased. (B)
Cell viability was measured by recording the expression of an off-target gene — Renilla
luciferase and is relative to non-treated cells. In both graphs error bars represent the standard
deviation (N=8).
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Cellular uptake of lipid–PEI–siRNA complexes. The uptake of lipid–PEI compounds
complexed with Cy5-labled siRNA by HeLa cells was imaged using an Opera spinning disk
confocal microscope. The uptake of the lipid:PEI mole ratio of 0.56 (A) is compared to that
of lipid:PEI mole ratio of 2.91 (B). Five different representative images are presented for
each compound (i–v) and image (vi) represents an enlarged image. Punctate structures can
be noticed in panel A (vi), while cytoplasmic as well as punctuate structures can be seen in
panel B (vi). Blue is Hoechst dye.
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Binding affinity between alkane-modified PEI to siRNA. PEI with higher conjugation levels
had weaker binding affinity to siRNA in comparison to lower conjugation levels. This was
noticed when testing the affinity between modified PEI to siRNA at various N/P ratios (A),
and after incubating siRNA-complexed particles with heparin sodium salt (Sigma) at various
concentrations (B). Bands represent free (non-bound) siRNA as detected on an agarose gel.
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EM images of alkane-modified PEI particles. Alkane-modified PEI particles were stained
with phosphotungstate and imaged by EM. (A) particles at a lipid:PEI ratio of 0.56 were
clearly noticed on the grid; on the other hand, particles with a lipid:PEI ratio of 2.91 (B)
were unstable during the imaging preparation procedure, although silhouettes of the particles
could be noticed on the grid, and excess stained material was removed from the figure by
false coloring.
Schroeder et al. Page 13
J Control Release. Author manuscript; available in PMC 2013 October 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
